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Insulin-like growth factor-1 (IGF-1) has been described as an important factor in proliferation, cell survival and migration of multiple
myeloma (MM) cells. Angiogenesis correlates with development and prognosis of the MM disease. Vascular endothelial growth factor
(VEGF) is one of the prominent factors involved in this process. The different functions of IGF-1 were investigated in the 5TMM
mouse model with emphasis on proliferation, migration and VEGF secretion, and the signalling pathways involved. Western Blot
analysis revealed that ERK1/2 and Akt (PKB) were activated after IGF-1 stimulation. The activation of ERK1/2 was reduced by the
PI3K inhibitor Wortmannin, implying that the PI3K pathway is involved in its activation. Insulin-like growth factor-1 induced an increase
in DNA synthesis in MM cells, which was mediated by a PI3K/Akt-MEK/ERK pathway. Insulin-like growth factor-1 enhanced F-actin
assembly and this process was only PI3K mediated. Stimulation by IGF-1 of VEGF production was reduced by PD98059, indicating
that only the MEK–ERK pathway is involved in IGF-1-stimulated VEGF production. In conclusion, IGF-1 mediates its multiple effects
on MM cells through different signal transduction pathways. In the future, we can study the potential in vivo effects of IGF-1 inhibition
on tumour growth and angiogenesis in MM.
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Multiple myeloma (MM) represents a B-cell malignancy, char-
acterised by a monoclonal proliferation of the plasma cells in the
bone marrow (BM) where they secrete high levels of immunoglo-
bulins. The MM cells induce osteolysis, by activating osteoclasts,
and increase neovascularisation or angiogenesis (Vacca et al,
1994).
Insulin-like growth factor (IGF-1) is mainly produced in the
liver (Jones and Clemmons, 1995; Le Roith et al, 2001), but is also
produced in considerable quantities by other cells (e.g.BMstromal
cells) (Ferlin et al, 2000). We and others have shown that IGF-1
plays an important role in MM. Although IL-6 has mostly been
described as a proliferation factor for MM, it has become clear that
IGF-1 has an equally important proliferative and antiapoptotic
effect (Ferlin et al, 2000; Tu et al, 2000; Qiang et al, 2002). It could
be that IGF-1 plays an even more pivotal role in the survival of MM
cells as IL-6 independent lines still respond to IGF-1 (Ferlin et al,
2000; Qiang et al, 2002). Our group has demonstrated that IGF-1
serves as a chemoattractant for MM cells (Vanderkerken et al,
1999). As we have reported that MM cells have a postgerminal
origin (Bakkus et al, 1992), this implies that the cells then need to
enter or re-enter the BM where they interact with the BM stromal
cells and receive proliferation and survival signals (Caligaris-
Cappio et al, 1991; Uchiyama et al, 1993; Van Riet and Van Camp,
1993; Lokhorst et al, 1994). This migration from the vascular to the
extravascular compartment of the BM is called ‘homing’. Butcher
and Picker (1996) described the process of homing of lymphocytes
as a multistep event in which chemoattractants are essential to
attract and activate the lymphocytes.
Angiogenesis is a relatively new factor that plays a role in MM
development. The vascular endothelial growth factor (VEGF) has
been shown to be expressed in human MM (Vacca et al, 1999). Our
group has recently reported that the VEGF isoforms 120 and 164
are expressed in the 5TMM mouse model (Van Valckenborgh et al,
2002). Vascular endothelial growth factor has a vital role in
angiogenesis, as it is able to stimulate vascular permeability and is
an endothelial cell-specific mitogen (Connolly et al, 1989).
In this work, the role of IGF-1 in the 5T33MM model was
investigated, with special emphasis on the ability of IGF-1 to
stimulate proliferation, migration and VEGF secretion. The signal
transduction pathways that are activated in response to IGF-1 were
determined. We studied the two most well known, distinct
downstream pathways of IGF-1 namely the PI3K and the MAPK
pathway (Bornfeldt et al, 1994; Puglianiello et al, 2000; Tu et al,
2000; Qiang et al, 2002). The 5TMM model was used since this is
an ideal in vivo model for testing different inhibitors of IGF-1. The
5TMM cell lines originated spontaneously in aging C57BL/KaLwRij
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smice and have since been propagated in vivo by intravenous
transfer of the tumour cells in young syngeneic mice. This model is
representative for the human disease; the tumour cells have a
predominant localisation in the bone marrow, normal Ig
concentration is decreased and is associated with an increased
serum paraprotein that is correlated with the development of the
disease. The presence of the tumour cells in the BM is associated
with enhanced angiogenesis (Van Valckenborgh et al, 2002) and
induction of bone lesions. On a more cellular basis, a similar
profile of adhesion molecules and chemokine receptors is observed
and similar mechanisms are used to induce osteoclastogenesis
(Radl et al, 1979; Vanderkerken et al, 1997; Vanderkerken et al,
2000; Asosingh et al, 2000a).
We here demonstrate for the first time that IGF-1 stimulates
VEGF secretion by MM cells through activation of ERK.
Proliferation of the MM cells in response to IGF-1 was mediated
through a PI3K–ERK pathway, while migration was mediated
through PI3K. These in vitro data demonstrate the importance of
studies whereby IGF-1 function is inhibited in vivo. The 5TMM
model hereby offers a suitable model combining these in vitro data
with in vivo work.
MATERIALS AND METHODS
Animals
C57BL/KaLwRij mice were purchased from Harlan CPB (Horst,
The Netherlands). Mice were used when they were 6–10 weeks old.
They were housed and treated following the conditions approved
by the Ethical Committee for Animal Experiments, VUB (license
no. LA1230281). The animal ethics meet the standards required by
the UKCCCR Guidelines (UKCCCR, 1998).
MM models
The 5T33MM cells originated spontaneously in aging C57BL/
KaLwRij mice and have since been propagated by intravenous
transfer of the diseased marrow in young syngeneic mice. The
paraprotein was assessed by protein electrophoresis of the serum
samples. When the serum concentration reached 10mgml
 1, the
mice were killed and the BM was flushed out of the femurs and
tibiae and crushed out of the vertebrae. The BM cells were
suspended in serum-free medium (RPMI 1640 (GIBCO, Life
Technologies, Ghent, Belgium), supplemented with penicillin–
streptomycin, glutamine and MEM NEAA-pyruvate (GIBCO)). The
cells were then purified by Lympholyte M (Cedarlane, Hornby,
Canada) gradient centrifugation at 1000g for 20min. After
washing, the cells were further purified by centrifugation for
25min at 450g on a 70% iso-osmotic Percoll (Pharmacia, Uppsala,
Sweden) gradient. The cell band on top of the gradient contained
enriched 5T33MM cells, with a purity reaching 90–95%, as
measured by flow cytometric analysis. Viability was more than
95%.
Stimulations and inhibitions
The cells were kept in serum-free medium and were stimulated
with 100ngml
 1 recombinant human IGF-1 (animal/media grade,
Grow Pep Ltd, Adelaide, Australia), for all experiments except for
the thymidine incorporation assays where it was 10ngml
 1. The
inhibitors Wortmannin (Sigma, Irvine, UK), Ly294002 (Sigma),
PD98059 (Alexis, CA) and UO126 (Alexis) were added 30min prior
to IGF-1 stimulation at a concentration of 100nM,1 0mM,2 0mM and
25mM, respectively. The inhibitors were dissolved in DMSO. The
DMSO concentration was 0.001% and the same concentration was
used as vehicle. This DMSO concentration was tested on the MM
cells and no change in function was measured compared to
untreated cells.
Western blot analysis
The cells were first starved in serum-free medium for 1h to reduce
increased basal levels of ERK 1 and 2 and Akt before stimulating
them. After stimulation with IGF-1, the cell pellets were lysed in
lysis buffer containing 50mM Tris, 150mM NaCl, 1% NP40 and
0.25% sodium deoxycholate. The following protease and phospha-
tase inhibitors were added: 4mM Na3VO4 (Sigma), 1mM Na4P2O7
(Sigma), 50mM NaF (VWR, PA, USA), 5mM EDTA (VWR), 1mM
AEBSF (ICN, CA, USA), 2mgml
 1 aprotinin (Sigma), 50mgml
 1
leupeptin (Sigma), 50mgml
 1 pepstatin A (ICN), 500mgml
 1
trypsin inhibitor (Sigma), 10mM benzamidin (Sigma) and 2.5mM
pnp benzoate (Sigma). The cells were then cleared by centrifuga-
tion (5min, 13000g) and sample buffer was added. After boiling,
the samples were separated on a 10% SDS–PAGE and transferred
to PVDF membranes (Bio Rad, CA, USA). The membranes were
blocked with PBS containing 5% low fat milk and 0.1% Tween 20
and probed with the appropriate antibodies, namely anti-pThr
202/
Tyr
204 ERK, anti-pThr
180/Tyr
182p38 and anti-pThr
183/Tyr
185JNK.
For measuring total protein levels, the blots were stripped and
reprobed with pan Ab. Anti-p44/42MAPK, anti-p-T202/Y204 p44/
42MAPK, anti-Akt and the HRP-coupled secondary antibodies
anti-rabbit and anti-mouse were acquired from Westburg, MA,
USA, while anti-p-S473Akt was acquired from Biosource, CA, USA.
The bands were visualised using the ECL system (Amersham,
Buckinghamshire, UK).
Thymidine incorporation assays
Cells (1.10
6ml
 1) were incubated in serum-free medium with or
without IGF-1 for 17h, in the presence or absence of the inhibitors.
At 16h before harvesting, cells were pulsed with 1mCi (methyl-
3H)
thymidine (Amersham). Cells were harvested by a cell harvester
(Inotech, Wohlen, Switzerland) on paper filters (Filtermat A,
Wallac, Turku, Finland). Filters were dried for 1h in a 601C oven
and sealed in sample bags (Wallac) containing 4ml Optiscint
Scintillation Liquid (Wallac). Radioactivity was counted using a
1450 Microbeta Liquid Scintillation Counter (Wallac). Results are
expressed as the relative DNA synthesis: the amount of radio-
activity of the unstimulated cells was set to 1 and the fold increase
of the radioactivity (c.p.m.) of the stimulated cells compared to
this is shown.
Quantifying F-actin content
The MM cells were kept in serum-free medium and were
stimulated with IGF-1 for 10min. The cells were then fixed for
15min with 3% paraformaldehyde in PBS. Cells were washed with
PBS and quenched in 0.1 M glycine in PBS for 15min. After a
second wash, the cells were permeabilized with 0.2% Triton X-100
in PBS containing 1% bovine serum albumin (BSA, Boehringer
Manheim, SA, Germany) for 10min. The cells were then treated
with 0.5mM FITC-conjugated phalloidin (Molecular Probes, OR,
USA) for 30min. All the incubations were performed at room
temperature. After washing, the cells were analysed by flow
cytometric analysis (FACScalibur, Becton Dickinson, LA, USA).
These results are normalised similar to those of the thymidine
incorporation assay.
Vascular endothelial growth factor ELISA
Vascular endothelial growth factor ELISAs were performed
according to the manufacturer’s instructions (Quantikine M,
mouse VEGF ELISA, R&D systems, MN, USA). In short, MM cells
were kept in serum-free RPMI 1640 medium at a density of 1.10
6
cellsml
 1 with or without IGF-1 for 24 or 48h. Conditioned media
of the MM cells were brought on a plate coated with anti-VEGF.
After 2h, the plate was washed and an antibody against VEGF
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sconjugated to HRP was added. After another 2h, the plate was
washed and the substrate solution was added for 30min. Then the
reaction was stopped and the fluorescence was read on an ELISA
reader (Thermo Max, Molecular Devices, CA, USA) at 450nm with
a correction set to 540nm. The results were then plotted against
the standard curve to become the actual concentrations. These
results are normalized similar to those of the thymidine
incorporation assay.
RNA isolation and cDNA synthesis
Total RNA from 5 10
6 cells was isolated using the SV total RNA
isolation system (Promega, Madison, WI, USA) according to the
manufacturer’s instructions. The concentration and purity of RNA
were determined by spectrophotometric measurement (Gene
Quant II: Pharmacia Biotech, Cambridge, UK). The total RNA
was converted into cDNA by the superscript first-strand synthesis
system (GIBCO) using random hexamers as primers.
Real-time quantitative PCR
In real-time quantitative PCR, a dual-labelled fluorogenic probe
that contains a fluorescent reporter dye at the 50 end and a
quencher dye at the 30 end is used. When the probe is intact,
emission from the reporter dye is quenched by the quencher.
During the extension phase of PCR, the annealed probe is cleaved
by the 50 nuclease activity of Taq polymerase, releasing the
reporter from the quencher. This results in an increase of
fluorescence emission from the reporter dye, which can be
quantitatively detected by the ABI (Foster City, CA, USA) PRISM
7700 Sequence Detector. The amount of fluorescence measured in
a sample is proportional to the amount of specific PCR product
generated. By analysis of the data, the Ct value can be determined.
This parameter represents the PCR cycle at which an increase in
fluorescence is detectable above the baseline signal.
In the 5TMM model, only the VEGF 120 and 164 isoforms can be
detected (Van Valckenborgh et al, 2002). Primers and probe for
the detection of these isoforms were found in the article of Zhang
et al (2002) and purchased from Eurogentech (Seraing, Belgium).
Both isoforms share the common probe, 50-ACA GCA GAT GTG
AAT GCA GAC CAA AGA AAG-30 and the common forward
primer, 50-GCC AGC ACA TAG AGA GAA TGA GC-30. The VEGF
120 reverse primer was 50-CGG CTT GTC ACA TTT TCT GG-30,
while the VEGF 164 reverse was 50-CAA GGC TCA CAG TGA TTT
TCT GG-30. Primers were located in two different exons to
eliminate detection of genomic DNA. The endogenous reference
gene GAPDH was used to standardise the amount of sample RNA.
Primers and probes for GAPDH were purchased from ABI and
used according to the manufacturer’s instructions. The GAPDH
and VEGF probes were labelled with a quencher dye (TAMRA) and
a reporter dye (FAM for VEGF and VIC for GAPDH). Taqman PCR
was performed in a 25ml reaction mix containing 12.5ml2  
master mix (ABI), 200nM probe, 300nM forward primer, 300nM
reverse primer and 50ng cDNA for the detection of VEGF mRNA.
The PCR cycles consisted of an initial denaturation step at 951C for
10min followed by 40 cycles at 951C for 15s and 601C for 1min.
Each sample was amplified in triplicate. The relative standard
curve method was used to quantitate the relative VEGF expression
in the 5T33MM cells treated with IGF-1. Relative standard curves
(50, 10, 2, 0.4, 0.083ng) were prepared using cDNA from 5T33MM
control samples.
Data analysis real-time PCR
According to the manufacturer’s instructions, the relative standard
curve method was used. Standard curves were generated by
plotting Ct values against the log input amount of RNA. The input
amount of VEGF and GAPDH of unknown samples was calculated
with the following formula: log input amount¼(Ct value b)/m,
where b is the y intercept of the standard curve line and m is the
slope. Next, the amount of VEGF mRNA was divided by the
amount of GAPDH mRNA to determine the normalised amount of
VEGF mRNA. The value of the control sample was then set to 1 so
that the values of the IGF-1-treated samples would be expressed as
a fold increase.
Statistical analysis
For statistical analysis, the Mann–Whitney test was used. Pp0.05
was considered significant.
RESULTS
Activation of signal transduction elements in response to
IGF-1 stimulation
We have already shown by FACS analysis that the 5T33MM cells
express the IGF-1R (Asosingh et al, 2000b). As a first step in
defining the IGF-1 signalling pathways, the phosphorylation by
IGF-1 of the MAP kinases ERK1/2, p38 and JNK was determined.
The cells were stimulated with different concentrations of IGF-1
(Figure 1a) and for different time periods (Figure 1b). The MAPK
p38 and JNK were already phosphorylated in unstimulated cells,
and IGF-1 did not influence their phosphorylation state
(Figure 1b). ERK1/2 on the other hand became phosphorylated
after 5min stimulation with 100ngml
 1 IGF-1 and this activation
continued for at least 40min (Figure 1b).
To study the effect of IGF-1 on the PI3K pathway, the
phosphorylation of Akt (PKB) was investigated. Akt is a down-
stream target of PI3K-generated signals and becomes activated
after phosphorylation of Ser 473. In response to IGF-1 stimulation,
Akt became phosphorylated after 1min and an increased
level of phosphorylation was observed for at least 40min
(Figure 1b). Since Akt phosphorylation is completely inhibited
with PI3K inhibitors, Akt is a useful molecule to measure PI3K
activation (Figure 2).
Qiang et al (2002) recently described a crosstalk between the
MAPK pathway and the PI3K pathway in MM cells. To confirm
this, the PI3K inhibitors Ly294002 and Wortmannin and the MEK
inhibitors PD98059 and UO126 were used. As shown in Figure 2,
the MEK inhibitors only influenced the activation levels of ERK1/2.
The PI3K inhibitors on the other hand not only abolished the
phosphorylation of Akt but also abrogated the activation of ERK1/
2. Insulin-like growth factor-1 thus activates ERK1/2 through
activation of MEK via a PI3K signalling pathway. This hypothesis
is in accordance with our finding that stimulation of Akt
phosphorylation takes place before the increase in ERK phosphor-
ylation (Figure 1b).
Signal transduction in proliferation
Figure 3 shows that IGF-1 augments DNA synthesis by 100%.
Antiapoptotic effects of IGF-1 were measured with annexin V-PI
staining; IGF-1 induced only a 1–5% decrease in apoptosis and cell
death (data not shown). To address the signalling pathways
involved, the cells were preincubated with inhibitors of MEK or
PI3K. It appeared that Wortmannin and PD98059 reduced the
effect of IGF-1 by 60 and 90%, respectively. When PD98059 and
Wortmannin were added together, no additive effect was seen
(Figure 3). Both inhibitors had only a minor effect on the DNA
synthesis of unstimulated cells. As depicted in Figure 2, the PI3K
pathway influences the phosphorylation status of the ERKs.
Probably, the PI3K–MEK–ERK pathway mediates the DNA
synthesis of the MM cells in response to IGF-1.
Signalling pathways involved in the functions of IGF-1 in MM
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sSignal transduction in F-actin assembly
Our group has already described the chemotactic effect of IGF-1 on
the 5TMM cells (Vanderkerken et al, 1999; Asosingh et al, 2000b).
We have previously shown that F-actin assembly correlates with
MM cell migration (Menu et al, 2002). Therefore, in this study, F-
actin quantification was used as a measure of migration. Here we
studied, through F-actin quantification, the IGF-1 signalling
pathway that leads to F-actin assembly. Insulin-like growth
factor-1 significantly augmented the F-actin quantity and this
effect was completely abolished by Wortmannin, which had no
effect in the absence of IGF-1. PD98059 had no significant effect
(Figure 4), indicating that F-actin assembly in MM cells in
response to IGF-1 is mediated through the PI3K pathway and not
through the MEK–ERK cascade.
Signal transduction in VEGF secretion
We previously described that the 5TMM cells produce VEGF (Van
Valckenborgh et al, 2002). Figure 5 shows that IGF-1 increases
VEGF levels in the conditioned media of MM cells by 100% (up to
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Figure 1 Activation of the MEK–ERK and the PI3K pathway after IGF-1
stimulation. (A) 5T33MM cells were stimulated with increasing concentra-
tions of IGF-1 for 10min. (B) 5T33MM cells were stimulated during
different periods of time with 100ngml
 1 IGF-1. Equivalent amounts of
lysates were immunoblotted with anti-P-ERK1/2 (first panel), P-Akt (third
panel), P-Jnk (fifth panel) and P-p38 (seventh panel) and reblotted with
anti-ERK1/2 (second panel), anti-Akt (fourth panel), anti-JNK (sixth panel)
and anti-p38 (eigth panel) to confirm equal loading. One experiment
representative of four is shown.
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Figure 2 Crosstalk between the PI3K pathway and the MEK–ERK
pathway. The MEK inhibitors PD98059 and UO126 abolish stimulation by
IGF-1 of ERK phosphoryation but have no influence on the phosphorylation
of Akt (first and third panel). The inhibitors of the PI3K pathway
Wortmannin and Ly294002, on the other hand, inhibit the phosphorylation
of Akt (PKB), confirming that Akt becomes phosphorylated through
activation of the PI3K pathway (third panel), but also reduces the
phosphorylation of ERK1 and 2 (first panel). The cells were stimulated with
100ngml
 1 IGF-1 for 10min and lysates were treated as in the previous
figure. One experiment representative of four is shown.
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Figure 3 IGF-1 induced DNA synthesis. For the thymidine incorporation
assays, the MM cells were incubated with RPMI in the absence or the
presence of 10ngml
 1 IGF-1. Before stimulation with or without IGF-1, the
cells were preincubated for 30min with Wortmannin (100nM), PD98059
(20mM) or both where indicated. Mean values7s.d. for four independent
experiments are shown. (*: Po0.01 vs control, **: Po0.01 vs IGF-1, ***:
Po0.01 vs IGF-1).
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 1) within 24h. Flow cytometric analysis revealed that
there was only a 10–15% increase in cell number in response to
IGF-1 (data not shown), indicating that proliferation is not
responsible for the 100% increase in VEGF concentration. The
antiapoptotic effect of IGF-1 was also measured here through
annexin V-PI staining. There was only 1–5% decrease in apoptosis
and cell death in the IGF-1-stimulated group in this time frame
(results not illustrated). This result excludes the possibility that
IGF-1 increases VEGF secretion through inhibition of apoptosis.
Therefore, we conclude that IGF-1 stimulates VEGF secretion in
the 5T33MM cells. To determine whether the increase in
production of VEGF was regulated at the mRNA level, quantitative
real-time PCR was performed. In the 5TMM model, only the VEGF
120 and 164 isoforms are present (Van Valckenborgh et al, 2002).
Figure 6 shows that after 24h, the expression of the VEGF120
isoform was upregulated 1.8 times and that of VEGF164 2.8 times.
These results suggest that VEGF production by IGF-1 is, at least in
part, regulated at the mRNA level.
Next, the pathways through which IGF-1 stimulates VEGF
secretion were examined. The MEK inhibitor PD98059 reduced the
stimulation of VEGF production by approximately 75%, whereas
the PI3K inhibitor, Wortmannin, had no significant effect
(Figure 5). Both inhibitors had a minor or no effect on the
unstimulated VEGF production. These results suggest that VEGF
secretion by MM cells in response to IGF-1 is mediated by the
MEK–ERK pathway.
DISCUSSION
In spite of extensive research and the development of novel
therapies, MM remains a deadly malignancy. One of the main
characteristics of the disease is the restricted localisation of the
malignant plasma cells in the BM. This is most likely due to
selective homing and survival in the BM. ‘Homing’ is the process of
migration from the vascular to the extravascular compartment of
an organ. Butcher and Picker (1996) have described the homing
process as a multistep event. Our group has already demonstrated
the selective homing of the MM cells to the BM (Vanderkerken
et al, 2000). Once in the BM, the MM cells interact with the stromal
cells to receive proliferation and survival signals, unique to the
BM. Vacca et al (1994) have also stated that angiogenesis is
involved in MM and correlates with MM progression.
Insulin-like growth factor-1 is produced by the BM stromal cells
(Abboud et al, 1991; Ferlin et al, 2000) and has been implicated in
the development of MM. Our group has demonstrated that it acts
as a chemoattractant for MM cells (Vanderkerken et al, 1999), and
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Figure 4 IGF-1 induced F-actin assembly. The F-actin content of the MM
cells was measured by FACS analysis. The mean fluorescence intensity is
shown as the relative value compared to unstimulated cells. The cells were
stimulated with or without 100ngml
 1 IGF-1, after a 30min incubation
with Wortmannin (100nM) or PD98059 (20mM) where indicated. The cells
were then labelled with phalloidin FITC. Mean values7s.d. for three
independent experiments are shown (*: Po0.02 vs control, **: Po0.04,
***: P40.05 vs IGF-1).
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Figure 5 Stimulation by IGF-1 of VEGF secretion. The 5T33MM cells
were stimulated with or without 100ngml
 1 IGF-1 for 24h, after a 30min
incubation with Wortmannin (100nM) or PD98059 (20mM) where
indicated. Concentrations of VEGF are shown relative to unstimulated
cells. The maximum IGF-1-stimulated VEGF secretion reaches 250pgml
 1.
Mean values7s.d. for three independent experiments are shown (*:
Po0.01 vs control, **: Po0.01, ***: P40.05 vs 100ngml
 1 IGF-1).
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Figure 6 IGF-1 stimulates VEGF mRNA expression. The MM cells were
stimulated with 100ngml
 1 IGF-1 for 6 or 24h. The relative amount of
VEGF in the IGF-1-stimulated samples compared to the control samples is
shown. Error bars represent s.d. in the experiment. One experiment
representing three is illustrated, Po0.05.
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sthus plays a role in the process of homing. Insulin-like growth
factor-1 also stimulates the proliferation and survival of MM cells
(Freund et al, 1994; Georgii-Hemming et al, 1996; Ferlin et al, 2000;
Qiang et al, 2002) and has been described to increase the
expression of VEGF and thus angiogenesis in colon cancer cells
(Fukuda et al, 2002). In the present paper, we studied the in vitro
effects of IGF-1 on 5T33MM and the involvement of the different
signal transduction pathways in the stimulation of VEGF produc-
tion, proliferation and F-actin assembly. As mentioned previously,
the 5T33MM model is a suitable model representative for the
human disease, and allowing the combination of both in vitro and
in vivo experiments.
When IGF-1 binds to its receptor, it activates the tyrosine kinase
activity of the receptor leading to phosphorylation of tyrosine
residues on the receptor and IRS proteins. These tyrosine residues
serve as docking sites for SH2 domains on other signalling
molecules such as SHC or the p85 subunit of PI3K. Recruitment of
SHC to the IGF-1 receptor leads to activation of the MEK–ERK
pathway through activation of ras and raf (Jones and Clemmons,
1995; Le Roith et al, 2001). ERK is mostly known to be involved in
proliferation (Ferlin et al, 2000; Qiang et al, 2002), although several
groups have stated that in some cell types it could also be involved
in migration (Bonacchi et al, 2001; Delehedde et al, 2001;
Tanimura et al, 2002). The PI3K/Akt pathway is said to be an
antiapoptotic pathway in myeloma (Tu et al, 2000) although
numerous groups have found that PI3K plays a key role in
migration and gradient-sensing in other cell types (Gerszten et al,
2001; Comer and Parent, 2002; Curnock et al, 2002; Stephens et al,
2002; Weiner, 2002).
Our results show that the MEK–ERK pathway and the PI3K/Akt
pathway are activated in 5T33MM cells upon IGF-1 stimulation.
Activation of the PI3K pathway occurred before activation of the
MEK–ERK pathway. The other MAP kinases p38 and JNK were
already activated in unstimulated cells but their phosphorylation
status did not change after stimulation with IGF-1. We also
observed that treatment of the cells with the PI3K inhibitors
Wortmannin and Ly294002 led to inhibition of IGF-1-stimulated
ERK1/2 phosphorylation, indicating a regulatory role for the PI3K
pathway in the activation of ERK1/2. Qiang et al (2002) have also
seen this crosstalk in human myeloma cells. They showed that the
phosphorylation of MEK1/2 was also inhibited but not that of Raf,
an upstream kinase of MEK1/2, suggesting that the effect was at the
level of MEK1/2. In contrast, two groups reported that Akt could
influence the phosphorylation of Raf in other cell types, thereby
regulating the MEK–ERK pathway (Wennstrom and Downward,
1999; Zimmermann and Moelling, 1999). Since Akt is activated
sooner than ERK1/2 and the PI3K inhibitors can diminish ERK
phosphorylation, we propose a model of ERK activation through
the PI3K/Akt pathway in MM cells stimulated with IGF-1.
Our observation that inhibition of the MEK–ERK pathway as
well as inhibition of the PI3K pathway reduces the stimulation of
DNA synthesis by IGF-1 is in accordance with our hypothesis that
ERK is activated through stimulation of the PI3K pathway.
Although Qiang et al (2002) also showed that activation of ERK
in human MM cells is mediated by the PI3K pathway, they found
that only the PI3K pathway was involved in myeloma cell
proliferation. Our observation that the MEK inhibitor completely
blocks the stimulating effect of IGF-I on proliferation indicates
that the activation of ERK is essential for stimulation of 5T33MM
cell proliferation. The inhibitive effect of Wortmannin in our
experiments can obviously be explained by inhibition of ERK
activation. However, this does not exclude an additional role for
the PI3K pathway through stimulation of Akt in the stimulatory
effect of IGF-I on 5T33MM cell proliferation.
We have already described the migration of the 5TMM cells
towards IGF-1, but to our knowledge, no other group working on
MM has described the signal transduction involved. We have
already demonstrated by microscopy, fluometry and flow cyto-
metry that polarisation of MM cells and thus F-actin assembly
correlates with migration (Menu et al, 2002). Although the increase
in mean fluorescence intensity is rather small, it correlates well
with the polarisation seen by microscopy. When the F-actin
assembly is blocked, migration becomes impaired (Menu et al,
2002). Our finding that induction of F-actin assembly by IGF-1 was
blocked by the PI3K inhibitor but not by the MAPK inhibitor is in
line with most papers on the involvement of PI3K in chemotaxis
and migration. It has been proposed that PI3K regulates cell
migration through activation of Pyk2 and FAK (Reiske et al, 1999;
Rumsey et al, 2001; Franitza et al, 2002). Insulin-like growth
factor-1 thus attracts MM cells through a PI3K signalling
mechanism.
Although the importance of VEGF in MM has been described,
no group has shown that IGF-1 can induce VEGF secretion in MM
cells. We recently showed that the VEGF 120 and 164 isoform are
the only ones produced in the 5TMM mouse model (Van
Valckenborgh et al, 2002). Real-time Quantitative PCR revealed
that mRNA of both isoforms were upregulated in MM cells
stimulated with IGF-1. The secretion of the protein correlated
with the mRNA upregulation. Using MAPK and PI3K inhibitors, it
was found that the IGF-1-stimulated VEGF production is
mediated by the MEK/ERK pathway and not by PI3K since
Wortmannin had no significant effect on VEGF secretion. We
postulate that it is possible that activation of ERK occurs through
another pathway (e.g. the ras–raf pathway), later than the
PI3K-dependent one. This is in line with observations from other
groups (Miele et al, 2000; Kijowski et al, 2001; Fukuda et al, 2002)
showing that IGF-1-induced VEGF expression in colon cancer
cells and fibroblasts occurs through the MEK/ERK pathway.
The observation that IGF-1 can trigger VEGF production is a
novel finding and of importance. We can assume that when
IGF-1 stimulates VEGF secretion by the MM cells in the BM,
this will induce endothelial cell growth and vascularisation. As we
have already shown that the IGF-1R expression on MM cells
is upregulated after contact of the MM cells with BM endothelial
cells (Asosingh et al, 2000b), this enhanced vascularisation
will increase the effect of IGF-1 even further creating a repeating
circle. Moreover, BM endothelial cells can also support the
proliferation of MM cells in a way similar to fibroblasts (Szelenyi
et al, 2002). Podar et al (2001, 2002) have described that VEGF
on itself can also act as a migration and proliferation factor for
MM cells.
It has been reported that IGF-1 upregulates MMP-9 in breast
cancer cells (Mira et al, 1999). This matrix metalloproteinase is
involved in the invasion of the MM cells through the BM matrix.
We investigated whether IGF-1 can also upregulate MMP9 in our
model by gelatin zymography. However, IGF-1 did not affect
MMP9 secretion (data not shown).
In summary, MM cells are attracted to the BM by different
factors. Insulin-like growth factor-1 is identified as an in vitro
chemoattractant involved in this process and induces a clear
polarisation of the MM cells and a rearrangement of their F-actin.
Once the MM cells are in the vascular compartment, IGF-1 can
stimulate their growth and increases VEGF production. The latter
in turn stimulates their proliferation even more and enhances the
effect of IGF-1 through upregulation of the IGF-1R after contact
with the EC.
We have shown here that in the 5T33MM model, IGF-1 activates
similar functions and signalling pathways as in human cells.
Although difference in the usage of these pathways have been
found (e.g. the use of ERK activation for stimulation of
proliferation in 5T33MM cells), the 5T33MM model still allows
us to investigate the in vivo effects of specific inhibitors of the
signalling pathways or receptor tyrosine kinase inhibitors to
inhibit IGF-1 function in vivo and in this way study the potential
effects of IGF-1 inhibition on tumour growth and angiogenesis in
MM.
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